Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology
  • Year: 2017
  • Volume: 3
  • Issue: 4

Duloxetine-A novel therapeutic regimen for trigeminal neuralgia

Assistant Professor, Dept. of Oral Medicine & Radiology, Faculty of Dental Sciences, King George's Medical University, Lucknow

*Corresponding Author Email: chaurasiaakhilanand49@gmail.com

Online published on 3 April, 2018.

Abstract

Duloxetine is a potent and selective inhibitor of serotonin and noradrenaline transporters and a weak inhibitor of dopamine transporters. Duloxetine is highly protein bound and is widely distributed throughout tissues. It is rapidly and extensively metabolized in the liver by cytochrome P450 (CYP) 1A2 and 2D6 and its numerous metabolites which are inactive are mainly excreted in the urine. It is more effective for recurrent/refractory type of TN. Duloxetine holds the promise in complete remission of TN in future. So in coming days it may be a drug of choice for medical management of TN. This article is an insight in chemical features, pharmacodynamics, pathophysiology and therapeutics of Duloxetine.

Keywords

Antidepressants, Serotonin uptake inhibitors, Trigeminal Neuralgia, Major depressive disorders